Our Pipeline

Rich and diverse

Our numbers speak volumes. With more than 120 biologics in R&D and 40 products in clinical development, we have one of the strongest, most robust pipelines in the industry.


Cardiovascular and Metabolic diseases

Phase 1

Phase 1

  • MEDI0382 diabetes/obesity
  • MEDI4166 diabetes/cardiovascular
  • MEDI8111 trauma/bleeding

Phase 2

Phase 2

  • MEDI6012 ACS

Phase 3

Phase 3

Oncology

Phase 1

Phase 1

  • Iressa + durvalumab NSCLC
  • MEDI-551 + rituximab haematological malignancies
  • MEDI-565 solid tumours
  • MEDI0562 solid tumours
  • MEDI0639 solid tumours
  • MEDI0680 solid tumours
  • MEDI1873 solid tumours
  • MEDI3617 solid tumours
  • MEDI4276 solid tumours
  • MEDI6383 solid tumours
  • MEDI9197 solid tumours
  • MEDI9447 solid tumours
  • Tagrisso (AZD9291) + (durvalumab or selumetinib or savolitinib) TATTON advanced EGFRm NSCLC
  • durvalumab solid tumours
  • durvalumab + MEDI0680 solid tumours
  • durvalumab + MEDI6383 solid tumours
  • durvalumab + dabrafenib + trametinib melanoma
  • durvalumab + tremelimumab solid tumours

Phase 2

Phase 2

  • AZD5069+durvalumab AZD9150+durvalumab SCCHN
  • MEDI-551 diffuse B-cell lymphoma
  • MEDI-573 metastatic breast cancer
  • durvalumab solid tumours
  • durvalumab + tremelimumab gastric cancer

Phase 3

Phase 3

  • durvalumab PACIFIC stage III NSCLC
  • durvalumab HAWK 2nd-line SCCHN (PD-L1 positive)
  • durvalumab + tremelimumab ALPS metastatic pancreatic ductal carcinoma
  • durvalumab + tremelimumab ARCTIC 3rd-line NSCLC
  • durvalumab + tremelimumab CONDOR 2nd-line SCCHN (PD-L1 negative)
  • durvalumab + tremelimumab DANUBE 1st-line bladder
  • durvalumab + tremelimumab EAGLE 2nd-line SCCHN
  • durvalumab + tremelimumab KESTREL 1st-line SCCHN
  • durvalumab + tremelimumab MYSTIC 1st-line NSCLC
  • durvalumab + tremelimumab NEPTUNE 1st-line NSCLC
  • moxetumomab pasudotox PLAIT hairy cell leukaemia
  • tremelimumab DETERMINE mesothelioma

Respiratory, Inflammation and Autoimmunity

Phase 1

Phase 1

  • MEDI4920 primary Sjögren’s syndrome
  • MEDI5872 SLE
  • MEDI7836 asthma
  • anifrolumab systemic lupus erythematosus (subcutaneous)

Phase 2

Phase 2

  • MEDI-551 neuromyelitis optica
  • MEDI2070 Crohn’s disease
  • MEDI9929 asthma
  • abrilumab Crohn’s disease / ulcerative colitis
  • anifrolumab lupus nephritis
  • mavrilimumab rheumatoid arthritis
  • tralokinumab atopic dermatitis

Phase 3

Phase 3

  • anifrolumab TULIP systemic lupus erythematosus
  • benralizumab CALIMA SIROCCO ZONDA BISE BORA GREGALE severe asthma
  • benralizumab TERRANOVA GALATHEA COPD
  • brodalumab AMAGINE-1,2,3 psoriasis
  • tralokinumab STRATOS 1,2 TROPOS MESOS severe asthma

Infection, Neuroscience and Gastrointestinal

Phase 1

Phase 1

  • MEDI1814 Alzheimer’s disease
  • MEDI3902 prevention of nosocomial pseudomonas pneumonia

Phase 2

Phase 2

  • MEDI4893 hospital-acquired pneumonia/serious S. aureus infection
  • MEDI7510 prevention of RSV disease in older adults
  • MEDI8852 influenza A treatment
  • MEDI8897 passive RSV prophylaxis

Phase 3

Phase 3

  • MEDI-550 pandemic influenza prophylaxis

Terminations


AstraZeneca Pipeline

Together with AstraZeneca, we have an exciting and balanced pipeline underpinned by great science. Uniquely positioned with both large and small molecules, the development pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.